G1 Therapeutics, Inc.
Clinical trials sponsored by G1 Therapeutics, Inc., explained in plain language.
-
Could a bone marrow shield make chemotherapy safer for lung cancer patients?
Disease control CompletedThis study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were getting chemotherapy. The goal was to see if trilaciclib could protect the bone marrow and immune system from chemotherapy damage, reducing severe side effects like low white b…
Phase: PHASE1, PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a bone marrow shield improve chemo for aggressive lung cancer?
Disease control CompletedThis study tested whether adding a drug called trilaciclib to standard chemotherapy could protect the bone marrow and immune system in people with advanced small cell lung cancer. About 100 participants received either trilaciclib or a placebo alongside their chemo. The main goal…
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC